(2025)
Deep Learning Predicts EGFR Mutation Status from Histology Images in Non-Small Cell Lung Cancer.
Cancer Research Communications.
5,
12
(2025)
Linking p53 immunostaining to TP53 mutation status in patients with non-small cell lung cancer.
PATHOLOGY.
57,
7
(2025)
Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase 2 Trial.
JOURNAL OF THORACIC ONCOLOGY.
20,
12
(2025)
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
13,
10
(2025)
Evidential deep learning-based ALK-expression screening using H&E-stained histopathological images.
NPJ DIGITAL MEDICINE.
8,
1
(2025)
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.
TARGETED ONCOLOGY.
(2025)
Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial.
ECLINICALMEDICINE.
84,
(2025)
Indirect targeting of MYC and direct targeting in combination with chemotherapies are more effective than direct mono-targeting in triple negative breast cancer.
TRANSLATIONAL ONCOLOGY.
(2024)
Clinical and radiologic features of soft tissue sarcoma in trunk and extremities that underwent unplanned excision.
PLOS ONE.
19,
12 December
(2024)
Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer.
FRONTIERS IN ONCOLOGY.
14,
(2024)
Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.
CANCER IMMUNOLOGY IMMUNOTHERAPY.
73,
12
(2024)
The Growth of Screening-Detected Pure Ground-Glass Nodules Following 10 Years of Stability.
CHEST.
(2024)
Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05.
ESMO OPEN.
9,
10
(2024)
Real-time assessment of relative mitochondrial ATP synthesis response against inhibiting and stimulating substrates (MitoRAISE).
CANCER & METABOLISM.
12,
1
(2024)
Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine.
PATHOLOGY.
56,
5
(2024)
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine.
MODERN PATHOLOGY.
37,
6
(2024)
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
BMC CANCER.
24,
1
(2024)
Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.
JCO PRECISION ONCOLOGY.
8,
(2024)
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
EBIOMEDICINE.
102,
(2024)
Role of invasive mediastinal nodal staging in survival outcomes of patients with non-small cell lung cancer and without radiologic lymph node metastasis: a retrospective cohort study.
eClinicalMedicine.
69,
학술회의논문
(2011)
Comparision of peptide nucleic acid(PNA)-mediated PCR clamping, COLD-PCR, and direct sequencing in detection of PIK3CA, BRAF and KRAS mutations in colorectal cancers.
Association of Molecular Pathology.
미국
(2011)
IDH1 mutation is a favorable prognostic factor for type 2 gliomatosis recebri.
Association of Molecular Pathology.
미국
(2011)
Testing Practices for EGFR and KRAS in Advanced Non-Small Cell Lung Cancer in a Comprehensive Cancer Care Setting in Korea.
European Society for Medical Oncology.
스웨덴
(2011)
Detection of MDM2 and CDK4 by Fluorescence in Situ Hybridization, Immunohistochemistry and Real-time PCR in Liposarcoma:Prognositic Significance based on the Molecular Diagnosis.
USCAP.
미국